scholarly journals Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery

Small ◽  
2016 ◽  
Vol 13 (10) ◽  
pp. 1603121 ◽  
Author(s):  
Zhiwei Xie ◽  
Yixue Su ◽  
Gloria B. Kim ◽  
Erhan Selvi ◽  
Chuying Ma ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Immune Cell ◽  
Theranostic Nanoparticles

scholarly journals Drug Delivery: Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery (Small 10/2017)

Small ◽  
2017 ◽  
Vol 13 (10) ◽  
Author(s):  
Zhiwei Xie ◽  
Yixue Su ◽  
Gloria B. Kim ◽  
Erhan Selvi ◽  
Chuying Ma ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Immune Cell ◽  
Theranostic Nanoparticles

scholarly journals Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis

2018 ◽  
Vol 6 ◽  
Author(s):  
Antonio Cervadoro ◽  
Roberto Palomba ◽  
Giuseppe Vergaro ◽  
Roberta Cecchi ◽  
Luca Menichetti ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cardiovascular Diseases ◽  
Immune Cell

scholarly journals Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles

Theranostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 778-795 ◽  
Author(s):  
Minati Satpathy ◽  
Liya Wang ◽  
Rafal J. Zielinski ◽  
Weiping Qian ◽  
Y. Andrew Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Image Guided Therapy ◽  
Image Guided ◽  
Theranostic Nanoparticles ◽  
Targeted Drug ◽  
Guided Therapy

Toward theranostic nanoparticles: CB[7]-functionalized iron oxide for drug delivery and MRI

2013 ◽  
Vol 1 (38) ◽  
pp. 5076 ◽  
Author(s):  
Farah Benyettou ◽  
Irena Milosevic ◽  
Yoann Lalatonne ◽  
Fabienne Warmont ◽  
Rana Assah ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Iron Oxide ◽  
Theranostic Nanoparticles

scholarly journals Abstract 35: 3D in vitro system for immuno-oncology: Real-time imaging of drug delivery, tumoroids, and immune cell activity

2019 ◽  
Author(s):  
Eric O. McGhee ◽  
Alex J. McGhee ◽  
Derek L. Hood ◽  
Kylie E. Van Meter ◽  
Juan M. Urueña ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Real Time ◽  
Immune Cell ◽  
Cell Activity ◽  
In Vitro System ◽  
Real Time Imaging

scholarly journals Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy

2021 ◽  
Vol 13 (604) ◽  
pp. eabc8922
Author(s):  
Yi Sun ◽  
Wei Chen ◽  
Robert J. Torphy ◽  
Sheng Yao ◽  
Gefeng Zhu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tumor Microenvironment ◽  
Immune Cell ◽  
Vascular Dysfunction ◽  
Tumor Hypoxia ◽  
Tumor Vasculature ◽  
Poor Response ◽  
Response To Therapy ◽  
Mouse Tumor ◽  
Programmed Death

The immature and dysfunctional vascular network within solid tumors poses a substantial obstacle to immunotherapy because it creates a hypoxic tumor microenvironment that actively limits immune cell infiltration. The molecular basis underpinning this vascular dysfunction is not fully understood. Using genome-scale receptor array technology, we showed here that insulin-like growth factor binding protein 7 (IGFBP7) interacts with its receptor CD93, and we subsequently demonstrated that this interaction contributes to abnormal tumor vasculature. Both CD93 and IGFBP7 were up-regulated in tumor-associated endothelial cells. IGFBP7 interacted with CD93 via a domain different from multimerin-2, the known ligand for CD93. In two mouse tumor models, blockade of the CD93/IGFBP7 interaction by monoclonal antibodies promoted vascular maturation to reduce leakage, leading to reduced tumor hypoxia and increased tumor perfusion. CD93 blockade in mice increased drug delivery, resulting in an improved antitumor response to gemcitabine or fluorouracil. Blockade of the CD93 pathway triggered a substantial increase in intratumoral effector T cells, thereby sensitizing mouse tumors to immune checkpoint therapy. Last, analysis of samples from patients with cancer under anti–programmed death 1/programmed death-ligand 1 treatment revealed that overexpression of the IGFBP7/CD93 pathway was associated with poor response to therapy. Thus, our study identified a molecular interaction involved in tumor vascular dysfunction and revealed an approach to promote a favorable tumor microenvironment for therapeutic intervention.

Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected drug-free anticoagulant activity

Nanomedicine ◽  
2020 ◽  
Vol 15 (14) ◽  
pp. 1361-1373
Author(s):  
James J Hobson ◽  
Steve P Rannard ◽  
Andrew Owen ◽  
Neill J Liptrott
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Safety Assessment ◽  
Cell Function ◽  
Immune Cell ◽  
Anticoagulant Activity ◽  
Drug Free ◽  
Preclinical Safety

Aim: A preclinical safety assessment of a novel nanoemulsion drug-delivery system, initially developed to improve the posology of efavirenz (EFV), was conducted with a specific focus on possible immunological and hematological complications. Materials & methods: Assessment of common acute toxicities, such as complement activation and cytokine secretion, was performed using validated assays known to have good correlation with in vivo end points. Results & conclusion: Compared with a standard aqueous solution of EFV, the EFV nanoemulsion showed no significant effect on immune cell function or phenotype. Prolongation of activated partial thromboplastin time was observed for EFV-loaded nanoemulsions (88% at 4 μg/ml) as well as unloaded nanoemulsions (52%) highlighting the potential for drug-free anticoagulant activity and warranting further investigation of the mechanism and utility of these materials.

Sign in / Sign up

Export Citation Format

Share Document